Giovanna Rege-Cambrin Selected Research

BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)

10/2022	Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study.
10/2021	Droplet Digital PCR for BCR-ABL1 Monitoring in Diagnostic Routine: Ready to Start?
1/2021	Genetic Screening for Potential New Targets in Chronic Myeloid Leukemia Based on Drosophila Transgenic for Human BCR-ABL1.
1/2019	Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.
1/2018	Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series.
11/2016	Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome.
1/2016	Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia.
1/2016	Dasatinib first-line: Multicentric Italian experience outside clinical trials.
1/2016	Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.
4/2015	The choice of first-line chronic myelogenous leukemia treatment.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Giovanna Rege-Cambrin Research Topics

Disease

25	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 10/2022 - 07/2002
6	Philadelphia Chromosome 01/2021 - 06/2002
5	Leukemia 12/2019 - 06/2002
4	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 09/2013 - 05/2007
3	Neoplasms (Cancer) 01/2021 - 01/2017
2	Residual Neoplasm 10/2021 - 02/2002
2	Cytopenia 04/2020 - 10/2007
2	Pleural Effusion (Pleural Effusions) 01/2018 - 10/2011
2	Chromosome Aberrations (Chromosome Abnormalities) 04/2015 - 07/2012
2	Blast Crisis (Blast Phase) 11/2011 - 12/2008
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2011 - 02/2002
2	Pathologic Complete Response 02/2009 - 12/2008
1	Infections 01/2022
1	Hematologic Diseases (Blood Diseases) 12/2019
1	Genomic Instability 04/2015
1	Acute Promyelocytic Leukemia 08/2014
1	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 08/2014
1	Lung Neoplasms (Lung Cancer) 10/2011
1	Breast Neoplasms (Breast Cancer) 10/2011
1	Head and Neck Neoplasms (Head and Neck Cancer) 10/2011
1	Febrile Neutropenia 10/2007
1	Drug-Related Side Effects and Adverse Reactions 10/2007

Drug/Important Bio-Agent (IBA)

17	Imatinib Mesylate (Gleevec)FDA Link 11/2016 - 09/2004
12	Tyrosine Kinase InhibitorsIBA 01/2022 - 12/2004
4	Dasatinib (BMS 354825)FDA Link 01/2018 - 10/2007
3	Proteins (Proteins, Gene)FDA Link 01/2021 - 12/2004
2	nilotinib FDA Link 10/2022 - 01/2016
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2021 - 12/2004
2	Interferon-alpha (Interferon Alfa)IBA 08/2010 - 05/2008
2	bcr-abl Fusion ProteinsIBA 12/2004 - 09/2004
1	Messenger RNA (mRNA)IBA 10/2021
1	eltrombopag FDA Link 04/2020
1	amsonic acid (DAS)IBA 01/2018
1	CalreticulinIBA 01/2017
1	Janus Kinase 2IBA 01/2017
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 08/2014
1	Pharmaceutical PreparationsIBA 10/2011
1	SuspensionsIBA 10/2011
1	Biomarkers (Surrogate Marker)IBA 02/2009
1	SteroidsIBA 05/2007
1	MB 5IBA 07/2002

Therapy/Procedure

15	Therapeutics 01/2022 - 02/2002
2	Stem Cell Transplantation 11/2011 - 12/2008
1	Polypharmacy 11/2016
1	Transplantation 11/2011
1	Drug Tapering 10/2007
1	Drug Therapy (Chemotherapy) 05/2007
1	Bone Marrow Transplantation (Transplantation, Bone Marrow) 02/2002